Aardvark is a distressed cash-backed biotech option whose upside depends on rescuing ARD-101 from an FDA clinical hold before cash burn, dilution, and Soleno’s first-mover lead overwhelm the investment thesis.
Overview
Aardvark Therapeutics is a pre-revenue clinical-stage biotech developing oral, gut-restricted therapies for hunger-driven metabolic disorders, especially Prader-Willi Syndrome and hypothalamic obesity. Its lead asset, ARD-101, targets bitter taste receptors in the gut to trigger endogenous satiety signaling with minimal systemic absorption. The opportunity is large and clinically meaningful, but the company currently has no commercial revenue, relies entirely on equity funding, and faces severe regulatory uncertainty after cardiac safety signals triggered trial pauses and an FDA clinical hold across ARD-101 development.